Sarepta Therapeutics (NASDAQ:SRPT) had its price objective reduced by Robert W. Baird from $202.00 to $181.00 in a research note released on Tuesday morning, The Fly reports. Robert W. Baird currently has an outperform rating on the biotechnology company’s stock.
Other research analysts also recently issued reports about the company. Zacks Investment Research upgraded Sarepta Therapeutics from a hold rating to a buy rating and set a $130.00 target price on the stock in a research note on Wednesday, May 8th. ValuEngine downgraded Sarepta Therapeutics from a buy rating to a hold rating in a research note on Thursday, August 8th. Citigroup dropped their target price on Sarepta Therapeutics from $201.00 to $190.00 and set a buy rating on the stock in a research note on Thursday, May 16th. Evercore ISI restated a buy rating and set a $200.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, August 8th. Finally, BidaskClub downgraded Sarepta Therapeutics from a hold rating to a sell rating in a research note on Wednesday, August 14th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and twenty-one have given a buy rating to the company. The stock presently has an average rating of Buy and an average price target of $197.78.
Shares of NASDAQ:SRPT opened at $93.61 on Tuesday. Sarepta Therapeutics has a 12-month low of $90.24 and a 12-month high of $165.87. The business’s fifty day simple moving average is $139.42 and its 200-day simple moving average is $130.16. The company has a current ratio of 8.81, a quick ratio of 7.84 and a debt-to-equity ratio of 0.44. The company has a market capitalization of $6.96 billion, a PE ratio of -17.14 and a beta of 2.01.
Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, August 7th. The biotechnology company reported ($3.74) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.08) by ($2.66). Sarepta Therapeutics had a negative return on equity of 55.37% and a negative net margin of 165.52%. The business had revenue of $94.67 million for the quarter, compared to analysts’ expectations of $91.05 million. During the same quarter last year, the firm earned ($1.67) earnings per share. The firm’s quarterly revenue was up 28.8% compared to the same quarter last year. Research analysts predict that Sarepta Therapeutics will post -4.94 EPS for the current year.
In other news, Director Richard Barry purchased 3,700 shares of the stock in a transaction on Wednesday, August 14th. The stock was bought at an average price of $122.50 per share, with a total value of $453,250.00. Following the transaction, the director now owns 3,177,065 shares in the company, valued at approximately $389,190,462.50. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Douglas S. Ingram purchased 16,252 shares of the stock in a transaction on Monday, August 12th. The shares were purchased at an average cost of $123.07 per share, with a total value of $2,000,133.64. Following the transaction, the chief executive officer now owns 424,405 shares in the company, valued at approximately $52,231,523.35. The disclosure for this purchase can be found here. In the last ninety days, insiders have acquired 26,252 shares of company stock valued at $3,109,234. 6.60% of the stock is currently owned by insiders.
Institutional investors and hedge funds have recently modified their holdings of the business. Wealthstreet Investment Advisors LLC lifted its position in Sarepta Therapeutics by 147.9% during the 1st quarter. Wealthstreet Investment Advisors LLC now owns 6,520 shares of the biotechnology company’s stock worth $777,000 after acquiring an additional 3,890 shares during the period. Cooper Haims Advisors LLC acquired a new position in shares of Sarepta Therapeutics in the 1st quarter valued at about $953,000. Quadrant Capital Group LLC acquired a new position in shares of Sarepta Therapeutics in the 1st quarter valued at about $51,000. Boston Advisors LLC lifted its holdings in shares of Sarepta Therapeutics by 43.4% in the 1st quarter. Boston Advisors LLC now owns 11,255 shares of the biotechnology company’s stock valued at $1,341,000 after buying an additional 3,405 shares during the period. Finally, BB&T Corp lifted its holdings in shares of Sarepta Therapeutics by 12.3% in the 1st quarter. BB&T Corp now owns 4,262 shares of the biotechnology company’s stock valued at $508,000 after buying an additional 468 shares during the period. 93.59% of the stock is owned by institutional investors.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.
Further Reading: Marijuana Stocks Investing Considerations
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.